Researchbxcl501opioid withdrawalclinical trialbioxcel therapeutics
BioXcel Therapeutics Reports Positive Phase 2 Results For Opioid Withdrawal
3.8
BioXcel Therapeutics announced positive Phase 2 topline results from a Columbia University, NIDA-funded study, reporting BXCL501 demonstrated clinical benefits and an overall favorable tolerability profile for treating opioid withdrawal symptoms.
Key Points
- 1Reports positive Phase 2 topline results showing BXCL501 clinical benefits and favorable tolerability
- 2Study led by Columbia University and funded by NIDA supports BXCL501 clinical evaluation
- 3Suggests potential progression toward later-stage development for opioid withdrawal pending full data disclosure
Scoring Rationale
Notable Phase 2 topline result but RSS-only company summary and limited public detail reduce confidence and impact.
Sources
Public references used for this report.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
250 free problems · No credit card
See all Health & Insurance problems
